Clinical trials: Bladder Tumors
Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma
Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
Objectives: Primary: Safety and tolerability of therapy with daratumumab in a cohort of patients with metastatic renal cell carcinoma and a cohort of patients with muscle invasive bladder cancer. Secondary: 1A.
- Conditions
- Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma, Malignant Urinary System Neoplasm, Metastatic Kidney Carcinoma
- Trial name
- NCT03473730
- Testing
- Biopsy, Daratumumab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
Bladder Cancer, Non Muscle Invasive Bladder Cancer
Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
The START study is a multicentre retrospective project. The aim is to identify clinico-pathological predictors of residual tumor at time of second transurethral resection of bladder tumor (re-TURBt) and to identify well-selected…
- Trial name
- START (NCT06205277)
- Testing
- Second TURBt
- Where
- Italy
- Volunteers
- 1,300 people
- Sponsor
- University of Trieste
Postoperative Urinary Retention (POUR)
Efficacy of Acupuncture for Postoperative Urinary Retention Following Radical Hysterectomy for Cervical Cancer
The goal of this clinical trial is to learn if acupuncture works to treat postoperative urinary retention in patients who have undergone radical hysterectomy for cervical cancer.
- Trial name
- APOUR (NCT07711977)
- Testing
- Acupuncture
- Volunteers
- 324 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Renal Cell Carcinoma, Urothelial Carcinoma
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
This is a comparative study using resected/ biopsied tumors samples collected from renal cell carcinoma and urothelial carcinoma patients who underwent surgical removal of lesions, followed by immune checkpoint blockade (ICB)…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
- Trial name
- NCT03291028
- Testing
- Immune checkpoint inhibitor targeting PD1
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Fox Chase Cancer Center
Muscle Invasive Bladder Cancer Urothelial Carcinoma
Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study
This is a single-arm, open-label, multicenter clinical trial to investigate the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative treatment in patients with muscle-invasive bladder…
- Trial name
- NCT05328336
- Testing
- Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Tianjin Medical University Second Hospital
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014144
- Testing
- gefitinib
- Where
- 95 sites in United States
- Volunteers
- 31 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer Stage 0, Bladder Cancer Stage I
Efficacy and Safety of Obturator Nerve Block During Transurethral Resection on Non-muscle Invasive Intermediate and High Risk Lateral Wall Bladder Tumours
In this prospective randomized controlled study, the effects of obturator nerve block (ONB) on obturator reflex, incomplete resection, perforation, tumor recurrence and progression, presence of muscle tissue in the specimen, need…
- Trial name
- NCT04885309
- Testing
- Nerve Stimulator-guided Obturator Nerve Block
- Where
- Turkey (Türkiye)
- Volunteers
- 104 people
- Sponsor
- Ankara Training and Research Hospital
Bladder Cancer
A Study of Avelumab in Real-World Treatment for Patients With Advanced or Metastatic Urothelial Cancer
This ambispective (both retrospective and prospective) NIS will evaluate the effectiveness and safety of Avelumab as a maintenance therapy administered after completion of first-line platinum-based chemotherapy in patients with…
- Trial name
- NCT05568407
- Testing
- Avelumab
- Where
- 7 sites in Argentina, Brazil
- Volunteers
- 19 people
- Sponsor
- Pfizer
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
This study evaluates the effect of bladder cancer treatment on quality of life.
- Conditions
- Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8
- Trial name
- NCT06350734
- Testing
- Non-Interventional Study
- Where
- 3 sites in United States
- Volunteers
- 204 people
- Sponsor
- Mayo Clinic
Asymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying, Asymptomatic Bacteriuria in Subjects Relying on Some Type of Catheter
Effects of Microbiological and Immunological Factors on the Lower Urinary Tract
Millions of patients of all ages suffer worldwide from diverse urinary pathologies, such as lower urinary tract (LUT) dysfunction, bladder pain syndrome, urinary tract infections (UTIs), or bladder cancer.
- Conditions
- Asymptomatic Bacteriuria in Subjects Not Requiring Assisted Bladder Emptying, Asymptomatic Bacteriuria in Subjects Relying on Some Type of Catheter, Recurrent Non-catheter Associated UTIs, Acute Catheter-associated UTI (CAUTI)
- Trial name
- MiLUT (NCT07494864)
- Where
- Switzerland
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Urothelial Carcinoma Ureter, Urothelial Cancer of Renal Pelvis
Intravesical Mitomycin C After Diagnostic Ureteroscopy for Upper Tract Urothelial Carcinoma
The objective of this pilot study is to determine the feasibility of conducting a phase III randomized trial of intravesical mitomycin C (MMC) for prevention of intravesical recurrence (IVR) after diagnostic ureteroscopy for…
- Trial name
- NCT05979909
- Testing
- Mitomycin C
- Volunteers
- 40 people
- Sponsor
- McMaster University
Bladder Cancer, Biomarker
Urine-DNA Biomarkers in Detecting Bladder Cancer
DNA biomarkers in urine are important diagnostic and prognostic indicators for bladder cancer. Many genetic alterations have been identified in the urinary DNA.
- Conditions
- Bladder Cancer, Biomarker, Diagnosis, Urine
- Trial name
- NCT03066310
- Testing
- Next generation sequencing
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Xiangya Hospital of Central South University
Advanced Urothelial Carcinoma
Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer
This study aims to determine whether adding an oral medication called Capivasertib to ongoing immunotherapy can enhance treatment responses in patients with advanced bladder cancer (aBC), as well as to evaluate the safety of this…
- Trial name
- NCT07793578
- Testing
- capivasertib
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer, Bladder Cancer
Assessing Financial Toxicity Using the PROFFIT Questionnaire in Patients Treated With Mini-invasive Approach for Urological Malignancies.
Patients previously treated with robotic surgery for urological cancers such as prostate, bladder and kidney cancer will be enrolled, in particular patients operated in the last twelve months will be included after signing the…
- Conditions
- Prostate Cancer, Bladder Cancer, Kidney Cancer
- Trial name
- NCT06955910
- Testing
- questionnaires
- Where
- Italy
- Volunteers
- 120 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Bladder Carcinoma
Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery
This phase III trial studies how well nutrition therapy works in improving immune system in patients with bladder cancer that can be removed by surgery.
- Trial name
- NCT03757949
- Testing
- Laboratory Biomarker Analysis, Nutritional Intervention, Quality-of-Life Assessment
- Where
- 46 sites in United States
- Volunteers
- 203 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure
To study the safety and efficacy of CG0070, an oncolytic virus expression GM-CSF in high grade non muscle invasive bladder cancer patients who failed BCG therapy and refused cystectomy.
- Trial name
- BOND2 (NCT02365818)
- Testing
- CG0070
- Where
- 17 sites in United States
- Volunteers
- 66 people
- Sponsor
- CG Oncology, Inc.
Bladder Cancer
PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
The primary objective of this study is to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of PF-07225570 alone or in combination with an anti-PD-1 antibody in participants with recurrent…
- Trial name
- NCT05259397
- Testing
- PF-07225570, sasanlimab
- Where
- 4 sites in United States, Poland
- Sponsor
- Pfizer
Cancer, Neoadjuvant Therapy
Development and Validation of a Multimodal Fusion Artificial Intelligence Model for Predicting the Efficacy of Neoadjuvant Treatment of Bladder Cancer
This study is a multi-center observational study without interventions, including the construction of an AI predictive model, with retrospective and prospective testing.
- Trial name
- NCT06909643
- Testing
- Artificial intelligence (AI)-based predictive model
- Where
- China
- Volunteers
- 469 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.